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TRPV1 receptors have classically been defined as
heat-sensitive, ligand-gated, nonselective cation
channels that integrate nociceptive stimuli in sensory
neurons. TRPV1 receptors have also been identified
in the brain, but their physiological role is poorly un-
derstood. Here we report that TRPV1 channel activa-
tion is necessary and sufficient to trigger long-term
synaptic depression (LTD). Excitatory synapses
onto hippocampal interneurons were depressed by
either capsaicin, a potent TRPV1 channel activator,
or the endogenously released eicosanoid, 12-(S)-
HPETE, whereas neighboring excitatory synapses
onto CA1 pyramidal cells were unaffected. TRPV1 re-
ceptor antagonists also prevented interneuron LTD.
In brain slices from TRPV1/mice, LTD was absent,
and neither capsaicin nor 12-(S)-HPETE elicited syn-
aptic depression. Our results suggest that, in the
hippocampus, TRPV1 receptor activation selectively
modifies synapses onto interneurons. Like other
forms of hippocampal synaptic plasticity, TRPV1-
mediated LTD may have a role in long-term changes
in physiological and pathological circuit behavior
during learning and epileptic activity.
INTRODUCTION
The TRPV1 channel, also known as vanilloid receptor VR1, was
cloned 10 years ago and is a member of a large family of cal-
cium-permeable nonselective cation channels (Caterina et al.,
1997; Szallasi and Blumberg, 1999). TRPV1 receptors are gated
by heat, low pH, or endogenous ligands termed ‘‘endovanilloids’’
including anandamide, lipoxygenase derivatives of arachidonic
acid, and long-chain, linear fatty acid dopamines such as
N-arachidonyldopamine (NADA) (Caterina et al., 1997; Tominaga
et al., 1998; Zygmunt et al., 1999; Hwang et al., 2000; Smart
et al., 2000; Huang et al., 2002; Shin et al., 2002; De Petrocellis
and Di Marzo, 2005; Matta et al., 2007). In the peripheral nervous
system (PNS), TRPV1 receptors are activated by thermal and
chemical stimuli, by capsaicin (8-methyl-N-vanillyl-6-nonena-
mide; the pungent ingredient of red hot chili peppers), and by746 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.the Euphorbia toxin resiniferatoxin, causing pain, inflammation,
and hyperalgesia. Bipolar neurons with unmyelinated axons
(C fibers) and somata in dorsal root and trigeminal ganglia, as
well as a subset of sensory neurons with thin myelinated axons
(Ad fibers), are capsaicin sensitive (Holzer, 1988). The TRP family
of proteins is currently under intense investigation in health and
disease because these ion channels respond to a diverse range
of stimuli and because of their widespread distribution in a num-
ber of organs and tissues. Currently, TRPV1 receptors are a novel
therapeutic target in the PNS, and agonists and antagonists are
being tested for the treatment of inflammatory and chronic
neuropathic pain (Szallasi and Appendino, 2004; Steenland
et al., 2006; Szallasi et al., 2006).
In contrast to the well-established function of TRPV1 recep-
tors in the PNS, their role in the central nervous system (CNS)
is not well defined. The presence of TRPV1 receptors in the
mammalian brain has been demonstrated using in situ hybridiza-
tion and reverse transcription-polymerase chain reaction (RT-
PCR) (Sasamura et al., 1998; Mezey et al., 2000), immunochem-
ical staining methods (Sanchez et al., 2001; Toth et al., 2005;
Cristino et al., 2006), and [3H]resiniferatoxin autoradiography
comparing wild-type and TRPV1 receptor knockout mice (Rob-
erts et al., 2004). These studies indicate the presence of poten-
tially functional TRPV1 receptors in brain regions including the
thalamic and hypothalamic nuclei, locus coeruleus, periaque-
ductal gray, cerebellum, cortical, and limbic structures including
the hippocampus, caudate putamen, and substantia nigra pars
compacta. Nonetheless, the functional significance of TRPV1 re-
ceptor expression in the brain remains elusive, although there is
evidence that TRPV1 receptors in the CNS are involved in pain
modulation and might serve as useful drug targets (Cui et al.,
2006). TRPV1 receptor mRNA and protein are expressed in hip-
pocampal neurons (Sasamura et al., 1998; Roberts et al., 2004;
Toth et al., 2005; Cristino et al., 2006) including those of the hu-
man hippocampus (Mezey et al., 2000), and functional effects of
these receptors have been shown using electrophysiological
methods (Al-Hayani et al., 2001; Huang et al., 2002; Marsch
et al., 2007). A recent study using mice lacking TRPV1 receptors
suggests their involvement in anxiety-related behavior and two
behavioral measures of hippocampal-dependent learning, con-
ditioned and sensitized fear (Marsch et al., 2007). Moreover, hip-
pocampal long-term potentiation (LTP) was attenuated in the
CA1 region of brain slices from Trpv1 knockout mice, indicating
alterations in synaptic circuit function in this brain region, al-
though the mechanism remains unknown (Marsch et al., 2007).
Neuron
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PNS to be activated by heat or low pH, and therefore it has
been suggested that other endogenous ligands of this ion chan-
nel, such as the endovanilloids mentioned above, are likely acti-
vators (Huang et al., 2002; Marinelli et al., 2003; Van Der Stelt and
Di Marzo, 2004; De Petrocellis and Di Marzo, 2005; Marsch et al.,
2007). Anandamide and NADA are also members of the endo-
cannabinoid family, activating CB1 receptors as well (Zygmunt
et al., 1999; Huang et al., 2002), and it remains unclear whether
or not any of these ligands are responsible for the TRPV1-medi-
ated physiological and pathological effects in and outside of the
CNS (Van Der Stelt and Di Marzo, 2004).
Synaptic plasticity in the brain is a fundamental process
underlying information storage and adaptation to external stimuli
(Malenka and Bear, 2004), and the cellular mechanisms underly-
ing synaptic plasticity are of great interest because manipulation
of these mechanisms could be used to modify neural function.
Plasticity of synapses onto GABAergic interneurons can modify
the output of cortical circuits, because interneurons are essential
in the precise control of firing of groups of principal cells as well
as in network oscillations (Kullmann and Lamsa, 2007; Mann
and Paulsen, 2007). Some years ago, we demonstrated that fol-
lowing high-frequency afferent stimulation, excitatory synapses
onto CA1 hippocampal interneurons exhibit long-term depres-
sion (LTD) (McMahon and Kauer, 1997). Here we report that
TRPV1 channel activation is a novel cellular element required
for this form of LTD.
RESULTS
In rat brain slices, AMPA receptor-mediated excitatory postsyn-
aptic currents (AMPAR EPSCs) were locally stimulated and re-
corded from hippocampal CA1 interneurons in stratum radiatum.
Because NMDA receptor (NMDAR) activation is an essential
component of many forms of synaptic plasticity, we first asked
whether LTD at these synapses requires NMDARs. In the pres-
ence of D-AP5 (50 mM), high-frequency electrical stimulation
(HFS) of glutamatergic afferents triggered robust depression of
EPSCs onto interneurons, indicating that NMDARs are not nec-
essary for LTD induction (Figures 1A and 1B; EPSC amplitudes
15–20 min post-HFS: 62.0% ± 5.3% of control values before
HFS; p < 0.001, n = 26). These values are similar to those found
previously in the absence of D-AP5 (McMahon and Kauer, 1997),
and all subsequent experiments were carried out in the presence
of the NMDAR antagonist. Stable LTD could be elicited even af-
ter 40 min in the whole-cell recording configuration (Figure 1B;
EPSC amplitudes 15–20 min post-HFS: 52.0% ± 23.2% of
control values before HFS; p < 0.05, n = 3). Hippocampal inter-
neurons are a diverse group of cells, expressing different neuro-
peptides and with different axonal innervation patterns (Freund
and Buzsaki, 1996; Parra et al., 1998). Nonetheless, synaptic
depression followed HFS in the majority of interneurons (26/29
experiments), supporting previous findings that distinct interneu-
ron classes in stratum radiatum can express this form of LTD
(McMahon and Kauer, 1997).
The most commonly observed mechanisms underlying synap-
tic depression are a decrease in presynaptic neurotransmitter
release or a decrease in postsynaptic receptor number orresponsiveness (Malenka and Bear, 2004). When synaptic plas-
ticity results from a change in neurotransmitter release, this is
generally accompanied by an altered coefficient of variation of
the EPSCs (CV) and changes in the paired-pulse ratio (PPR)
and synaptic failure rate (del Castillo and Katz, 1954; Malinow
and Tsien, 1990; Manabe et al., 1992). Consistent with this inter-
pretation, we observed a decrease in 1/CV2 and an increase in
the PPR and number of synaptic failures during LTD (Figures
1C–1E). If LTD at interneuron synapses results from a persistent
decrease in presynaptic glutamate release, we would also pre-
dict depression of the NMDAR-mediated component as well
as the AMPAR-mediated component of the EPSC (isolated in
the experiments in Figures 1A and 1B). We therefore measured
the isolated NMDAR-mediated EPSC at +40 mV and found
that HFS delivered to the afferents elicited robust LTD of the
NMDAR EPSC (Figures 1F and 1G; NMDAR EPSC amplitudes
post-HFS: 64.2% ± 11.1% of control values before HFS; p <
0.001, n = 7). Taken together, these findings indicate that LTD
is AMPAR and NMDAR independent and results from a persistent
decrease in presynaptic glutamate release as monitored by both
AMPA and NMDA receptors.
How might high-frequency activation of excitatory afferents
trigger LTD at interneuron synapses? Neither NMDARs nor AM-
PARs are necessary for LTD (Figure 1), but group I metabotropic
glutamate receptors (mGluRs) are expressed on these cells (Fer-
raguti et al., 2004) and will also be activated by the glutamate
released during HFS. We found that LTD was entirely blocked
in the presence of the selective mGluR1 antagonist CPCCOEt
(25–50 mM; Figure 2A; EPSC amplitudes 10–15 min post-HFS
in CPCCOEt: 111.4% ± 17.0% of control values before HFS;
p < 0.01 compared to control LTD, n = 9). Our findings thus far
are reminiscent of other recent examples of LTD in which activa-
tion of postsynaptic group I mGluRs produces endocannabi-
noids (Maejima et al., 2001; Gerdeman et al., 2002; Robbe
et al., 2002; Chevaleyre and Castillo, 2003, 2004; Ronesi et al.,
2004; Kreitzer and Malenka, 2005; Takahashi and Castillo,
2006). Endocannabinoids can act as retrograde messengers,
traveling across the synapse to activate presynaptic CB1 recep-
tors, thereby reducing presynaptic neurotransmitter release
(Llano et al., 1991; Pitler and Alger, 1992; Kreitzer and Regehr,
2001; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001).
To ask whether endocannabinoids might mediate LTD at inter-
neuron synapses, we tested two CB1 receptor antagonists.
SR141716A (rimonabant; 2–5 mM) effectively blocked LTD (Fig-
ure 2B; EPSC amplitudes 15–20 min post-HFS: 110.6% ±
19.3% of control values before HFS; p < 0.01 compared to con-
trol LTD, n = 10). However, the selective CB1 receptor antagonist
AM251 (2 mM) did not block LTD in any of the eight interneurons
tested (Figure 2C; EPSC amplitudes 15–20 min post-HFS:
48.6% ± 5.3% of control values before HFS, n = 8). To confirm
that AM251 indeed blocks CB1 receptors under these experi-
mental conditions, we found in separate experiments that
AM251 (2 mM) blocked the synaptic depression of these synap-
ses elicited by the CB1 receptor agonist WIN 55,212-2 (1 mM)
(Figures 2D and 2E; EPSC amplitudes after 10–15 min in WIN
55,212-2 alone: 66.1% ± 7.9% of pre-drug control values; p <
0.001, n = 14; EPSC amplitudes after 10–15 min in both WIN
55,212-2 and AM251: 101.7% ± 8.9% of pre-WIN 55,212-2Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 747
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TRPV1-Mediated LTDFigure 1. LTD at Excitatory Synapses on
Interneurons Is NMDAR Independent and
Is Maintained by a Decrease in Presynaptic
Glutamate Release
(A) A single experiment illustrating interneuron
LTD. NMDARs were blocked throughout the ex-
periment using 50 mM D-AP5. At the arrow, HFS
was delivered to the afferent pathway. The dotted
line in this and all other single examples is an ap-
proximation of the mean EPSC response before
HFS. Right panel: average of ten consecutive
EPSCs taken just before (black) and 20 min after
HFS (gray). Calibration: 100 pA, 10 ms.
(B) Left panel: averaged LTD experiments in the
presence of 50 mM D-AP5 (n = 26). The dotted
line in this and all other time course averages rep-
resents the mean normalized EPSC value before
HFS. Right panel: averaged LTD experiments in
which LTD was not triggered until 40 min following
break-in to the whole-cell configuration, showing
that the ability to induce LTD does not ‘‘wash
out’’ over this time period (n = 3). This and all other
experiments in the paper were carried out in the
presence of 50 mM D-AP5. Error bars indicate
mean ± SEM.
(C–E) Consistent with a presynaptic mechanism,
1/CV2 (squared mean EPSC amplitude divided
by EPSC variance) decreased, the PPR (EPSC2/
EPSC1) increased, and the number of synaptic
failures increased significantly during interneuron
LTD (average synaptic failures pre-HFS: 39.6% ±
3.3%; average synaptic failures post-HFS:
98.5% ± 0.7%; p < 0.001, n = 6). The paired-pulse
ratio (PPR) and coefficient of variation (1/CV2)
were calculated for 5 min epochs before and be-
tween 15 and 20 min after HFS (see Experimental
Procedures), and control cells with LTD of at least
10% in response to HFS were included in the PPR
and 1/CV2 analyses. Nonnormalized values of
1/CV2 (C), PPR (D), and synaptic failures (E) from
each interneuron are shown (open circles). The
thick black line and filled circles indicate the
mean value for all cells. Using nonnormalized
values, all points are significantly different from
pre-LTD values (p < 0.05).
(D) Inset: example traces of EPSCs taken just be-
fore (black) and after HFS-induced LTD (gray) are
shown, with the latter scaled so that the first
EPSCs are of the same size, illustrating the in-
creased paired-pulse ratio during LTD. Calibra-
tion: 100 pA, 10 ms.
(E) Inset: example traces illustrating consecutive EPSCs evoked using minimal stimulation before and during LTD from one experiment showing EPSCs identified
as synaptic failures (gray). Calibration: 25 pA, 25 ms. Stimulus artifacts have been truncated for clarity.
(F) NMDAR-mediated EPSCs were evoked while holding the interneuron at +40 mV, in the absence of D-AP5, and including 10 mM 6,7-dinitroquinoxaline-2,3-
dione (DNQX) in the bathing solution. At the arrow, HFS was delivered to the afferents with the interneuron in current-clamp mode. Inset: average of ten EPSCs
recorded just before (black) and at 20 min after HFS (gray). Calibration for inset: 300 pA, 20 ms.
(G) Averaged experiments showing LTD of NMDAR EPSCs recorded by holding the interneuron at +40 mV in the presence of 10 mM DNQX (n = 7).control values; p < 0.05 compared to WIN 55,212-2 depression
in the absence of AM251, n = 5). In addition, pretreatment with
WIN 55,212-2 (1 mM) for at least 10 min did not prevent synaptic
depression triggered by high-frequency synaptic stimulation
(EPSC amplitudes 15–20 min post-HFS: 51.3% ± 7.5% of
control values in WIN 55,212-2 before HFS; p = 0.25 compared
to control LTD, n = 12; data not shown). The block of LTD by748 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.SR141716A but not by AM251 was surprising, indicating that
CB1 receptors are not necessary for this form of LTD and instead
that SR141716A blocks LTD via a CB1 receptor-independent
mechanism.
SR141716A might antagonize not only CB1 receptors but also
the TRP channel family member TRPV1 (De Petrocellis et al.,
2001). TRPV1 is found in hippocampal neurons (Hajos and
Neuron
TRPV1-Mediated LTDFreund, 2002; Roberts et al., 2004; Toth et al., 2005; Cristino
et al., 2006; Marsch et al., 2007) and we therefore first tested
whether transient application of a TRPV1 agonist mimics LTD in-
duction. The extremely selective TRPV1 agonist capsaicin (1 mM)
significantly depressed excitatory synaptic currents in interneu-
rons (Figures 3A and 3B; EPSC amplitudes after 10–15 min
in capsaicin: 73.3% ± 4.6% of pre-drug control values; p <
0.001, n = 14). If capsaicin maximally activates signaling mech-
anisms in common with LTD, HFS following the synaptic depres-
sion elicited by capsaicin should not cause any further depres-
sion. As predicted, HFS after capsaicin exposure failed to
produce further LTD (Figures 3A and 3B; EPSC amplitudes
15–20 min post-HFS: 112.5% ± 21.9% of control values in cap-
saicin before HFS; p < 0.05 compared to control LTD, n = 10).
This result suggests that the processes underlying LTD induction
are fully activated by treatment with capsaicin, again supporting
the requirement for TRPV1 channels in LTD. Like synaptically
Figure 2. A Group I mGluR Antagonist and
SR141716A Block LTD, but AM251 Does Not
(A) Averaged data showing that when the group I
mGluR antagonist CPCCOEt (25–50 mM) was
bath applied for at least 10 min before HFS (arrow),
LTD was blocked in all but one cell (n = 9). Inset:
average of ten EPSCs from an example neuron be-
fore (black) or 20 min after HFS (gray). Calibration
for all insets: 100 pA, 10 ms.
(B) Averaged data showing that SR141716A
(2–5 mM) consistently blocked LTD (n = 10). Inset:
ten consecutive EPSCs from an example neuron
were averaged before (black) or 20 min after HFS
(gray).
(C) The CB1 receptor antagonist AM251 (2 mM) did
not affect LTD (average of eight experiments). In-
set: average of ten EPSCs taken from an example
neuron just before (black) and at 20 min after HFS
(gray).
(D) The CB1 receptor agonist WIN 55,212-2 (1 mM)
was bath applied and depresses synaptic trans-
mission at excitatory synapses onto interneurons
(n = 14). Inset: ten consecutive EPSCs taken
from an example neuron were averaged before
(black) or 10 min after the addition of WIN
55,212-2 (gray).
(E) The CB1 receptor antagonist AM251 (2 mM)
bath applied for at least 10 min prior to the addition
of WIN 55,212-2 prevents synaptic depression
(n = 5). Inset: average of ten EPSCs taken from an
example neuron just before (black) and at 10 min
after the addition of WIN 55,212-2 in the continued
presence of AM251 (gray). Error bars indicate
mean ± SEM.
induced LTD, the synaptic depression
elicited by capsaicin was accompanied
by an increase in synaptic failures, sup-
porting our hypothesis that LTD at inter-
neuron synapses results from a persistent
decrease in presynaptic glutamate re-
lease (Figure 3C; average synaptic fail-
ures pre-capsaicin application: 38.4% ±
3.5%; average synaptic failures in capsaicin: 73.5% ± 7.8%;
p < 0.01, n = 5).
We reasoned that if SR141716A blocks LTD by an antagonist
action at TRPV1 receptors on hippocampal neurons, then
SR141716A should also prevent capsaicin-induced synaptic
depression. After pretreatment with SR141716A (2 mM), capsai-
cin (1 mM) did not depress the synapses (Figure 3D; EPSC ampli-
tudes after 10–15 min in capsaicin and in the presence of
SR141716A: 102.8% ± 9.2% of pre-capsaicin control values;
p < 0.01 compared to capsaicin depression in the absence of
SR141716A, n = 6). This finding emphasizes that at this concen-
tration, SR141716A cannot be regarded as a selective CB1
receptor antagonist, but instead appears to antagonize capsai-
cin-sensitive receptors, presumably TRPV1 channels. If, as
these data suggest, TRPV1 is necessary for LTD induction at
interneuron synapses, then TRPV1 antagonists should interfere
with LTD. Both capsazepine (10 mM) and 50-iodoresiniferatoxinNeuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 749
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TRPV1-Mediated LTD(100 nM) potently blocked LTD when bath applied prior to HFS
(Figures 3E and 3F; EPSC amplitudes 15–20 min post-HFS in
capsazepine: 105.6% ± 8.6% of control values before HFS;
p < 0.001 compared to control LTD, n = 9; in 50-iodoresinifera-
toxin: 96.2% ± 13.6% of control values before HFS; p < 0.01
compared to control LTD, n = 7). These data support an essential
role for TRPV1 receptors in LTD induction. Once LTD is initiated,
TRPV1 channel activity is no longer necessary to maintain syn-
aptic depression because following LTD induction, EPSC ampli-
Figure 3. Capsaicin Mimics Interneuron
LTD via TRPV1 Receptors and TRPV1 Re-
ceptor Antagonists Block LTD Induction
(A) A single example illustrating that 12 min of
bath-applied capsaicin (1 mM) depresses EPSC
amplitudes so that no further depression is elicited
following HFS (arrow). Right inset, top panel: aver-
aged EPSCs taken just before (black) and after
10 min in capsaicin (gray). Lower panel: average
of ten EPSCs in capsaicin taken just before (black)
and at 20 min after HFS (gray). Calibration for all
insets: 100 pA, 10 ms.
(B) Left panel: 12 min of bath-applied capsaicin
(1 mM) depressed EPSC amplitudes (average of 14
experiments). Right panel: after capsaicin (1 mM)
caused a stable EPSC depression, HFS was deliv-
ered (arrow) but elicited no further depression
(average of ten experiments).
(C) Capsaicin (1 mM) application is associated with
an increase in synaptic failures using minimal stim-
ulation (p < 0.01). Percent failures for five experi-
ments are shown for the 10 min baseline period
just before capsaicin application and for the last
5 min in capsaicin. The thicker black line and filled
circles represent the average of five experiments.
(D) SR141716A (2 mM) prevents the synaptic de-
pression by capsaicin (1 mM), as expected if
SR141716A is blocking the capsaicin-sensitive re-
ceptors (average of six experiments). SR141716A
was bath applied for at least 10 min before the ap-
plication of capsaicin. Inset: averaged EPSCs from
an example neuron in SR141716A before (black)
and after 10 min in capsaicin (gray).
(E) Interneuron LTD was blocked by the TRPV1
receptor antagonist capsazepine (10 mM), bath-
applied prior to HFS (arrow) (average of nine
experiments). Inset: average of ten EPSCs from
an example neuron taken just before (black) and
at 20 min after HFS (gray).
(F) Bath-applied 50-iodoresiniferatoxin (100 nM),
another TRPV1 receptor antagonist, also blocked
LTD (average of seven experiments). Inset: aver-
age of ten EPSCs from an example neuron taken
just before (black) and at 20 min after HFS (gray).
Error bars indicate mean ± SEM.
tudes were not restored to basal values
by blocking TRPV1 receptors (10 mM
capsazepine was added 10 min after
HFS; EPSC amplitudes 10–15 min after
adding capsazepine: 50.1% ± 6.1% of
pre-HFS values, n = 6; data not shown).
The pharmacological data presented above are all consistent
with an essential role for TRPV1 channels in the induction of LTD.
To further test this hypothesis, we asked whether LTD could be
elicited in transgenic mice lacking the Trpv1 gene (Trpv1/)
(Caterina et al., 2000). LTD was markedly reduced in slices
from Trpv1/ mice when compared to LTD in interleaved slices
from wild-type control mice (Figures 4A and 4B; EPSC ampli-
tudes 15–20 min post-HFS in Trpv1/ mice: 95.8% ± 7.0% of
control values before HFS; p < 0.001 compared to control LTD750 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.
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TRPV1-Mediated LTDin wild-type mice, n = 9; in C57BL/6 wild-type mice: 52.1% ±
5.2% of control values before HFS, n = 15). Whereas application
of capsaicin (1 mM) to slices from wild-type mice elicited synaptic
depression, this was not seen in slices from Trpv1/ mice, con-
firming the lack of functional TRPV1 receptors (Figures 4C and
4D; EPSC amplitudes after 10–15 min in capsaicin in Trpv1/
Figure 4. Slices from Trpv1/ Mice Lack
Interneuron LTD and Capsaicin-Induced
Synaptic Depression
(A) In hippocampal slices from Trpv1/ mice, HFS
does not elicit LTD. Left panel: single experiment.
Inset: averaged EPSCs before and 15 min after
HFS. Calibration for all figure insets: 100 pA,
10 ms. Right panel: averaged experiments from
Trpv1/ mice (n = 9 animals).
(B) In slices from wild-type mice, HFS induces
LTD. Left panel: single experiment. Inset: aver-
aged EPSCs before and 15 min after HFS. Right
panel: averaged experiments from wild-type
mice (n = 15 animals). Experiments were inter-
leaved with those from Trpv1/ mice.
(C) Capsaicin (1 mM) has no effect on interneuron
synapses in slices from Trpv1/ animals. Left
panel: single experiment. Inset: averaged EPSCs
before and after 10 min in capsaicin. Capsaicin
(1 mM) was added as marked by the bar. Right
panel: averaged experiments from slices from
Trpv1/ mice (n = 8 animals).
(D) In slices from C57BL/6 wild-type mice, capsa-
icin (1 mM) elicits synaptic depression. Left panel:
single experiment. Inset: averaged EPSCs before
and after 10 min in capsaicin. Right panel: aver-
aged experiments from slices from C57BL/6
wild-type mice (n = 6 animals). Error bars indicate
mean ± SEM.
mice: 100.7% ± 6.6% of pre-drug control
values; p < 0.01 compared to capsaicin
response in wild-type mice, n = 8; EPSC
amplitudes after 10–15 min in capsaicin
in C57BL/6 wild-type mice: 50.5% ±
12.1% of pre-drug control values, n = 6).
These data complement the pharmaco-
logical evidence, and strongly suggest
that TRPV1 channels or TRPV1-contain-
ing heteromultimeric channels are signal-
ing components required for interneuron
LTD.
How is LTD initiated by high-frequency
synaptic stimulation? Our data are con-
sistent with a model analogous to that of
endocannabinoid-mediated LTD (Cheva-
leyre et al., 2006), in which activation of
mGluR1 produces a lipid retrograde mes-
senger capable of activating TRPV1 re-
ceptors located on presynaptic pyramidal
cell terminals. Activation of group I
mGluRs can produce both endocannabi-
noids and eicosanoid metabolites of
arachidonic acid, and these endogenous
messengers effectively activate TRPV1 receptors (Zygmunt
et al., 1999; Hwang et al., 2000; Shin et al., 2002). The eicosanoid
12-(S)-HPETE is known to be liberated during electrical stimula-
tion of hippocampal slices (Feinmark et al., 2003), and thus we
asked whether or not this lipid messenger can mimic LTD at in-
terneuron synapses. Application of 12-(S)-HPETE (100 nM)Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 751
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TRPV1-Mediated LTDFigure 5. The Endogenous TRPV1 Receptor
Agonist 12-(S)-HPETE Mimics LTD
(A) The endogenous TRPV1 receptor agonist 12-
(S)-HPETE (100 nM) was bath applied for 15 min
and depressed EPSC amplitudes (average of eight
experiments). Inset: average of ten EPSCs taken
from an example neuron just before (black) and
at 10 min after 12-(S)-HPETE application (gray).
Calibration for this and all insets: 100 pA, 10 ms.
(B) Following the bath application of 12-(S)-HPETE
for 15 min, resulting in a stable EPSC depression,
HFS (arrow) failed to induce further LTD (average
of six experiments). Inset: average of ten EPSCs
in 12-(S)-HPETE taken from an example neuron
just before (black) and at 20 min after HFS (gray).
(C) 12-(S)-HPETE (100 nM) application is associ-
ated with an increase in synaptic failures using
minimal stimulation (p < 0.001). Percent failures
for six experiments are shown for the 10 min base-
line period just before 12-(S)-HPETE application
and for the last 5 min in 12-(S)-HPETE. The thicker
black line and filled circles represent the average
of six experiments.
(D) Bath-applied baicalein (500 nM), a 12-lipoxy-
genase inhibitor, blocked LTD induction (average
of ten experiments). Inset: averaged EPSCs taken
from an example neuron before (black) or 20 min
after HFS (gray) in the presence of baicalein.
(E) The TRPV1 receptor antagonist capsazepine
(10 mM) prevents the synaptic depression caused
by 12-(S)-HPETE (100 nM), as expected if
12-(S)-HPETE acts as a TRPV1 receptor agonist
(average of six experiments). Inset: averaged
EPSCs taken from an example neuron in capsaze-
pine before (black) and after 10 min in 12-(S)-
HPETE (gray).
(F) SR141716A (2 mM) prevents the synaptic
depression resulting from the application of 12-
(S)-HPETE (100 nM) (average of five experiments).
Inset: averaged EPSCs taken from an example
neuron in SR141716A before (black) and after
10 min in 12-(S)-HPETE (gray).
(G) A single example illustrating that 12-(S)-HPETE
(100 nM) has no effect on interneuron synapses in
slices from Trpv1/ animals. Inset: averaged
EPSCs before and after 10 min in 12-(S)-HPETE.
12-(S)-HPETE was added as marked by the bar.
(H) Averaged experiments from slices from
Trpv1/ mice showing the lack of effect of
100 nM 12-(S)-HPETE (n = 6 animals). Error bars
indicate mean ± SEM.depressed excitatory synapses on interneurons (Figure 5A;
EPSC amplitudes after 10–15 min in 12-(S)-HPETE: 40.6% ±
11.7% of pre-drug control values; p < 0.01, n = 8), and subse-
quent HFS did not produce further LTD (Figure 5B; EPSC ampli-
tudes 15–20 min post-HFS: 98.7% ± 15.3% of control values in
12-(S)-HPETE before HFS; p < 0.05 compared to control LTD,
n = 6). In addition, the synaptic depression as a result of 12-(S)-752 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.HPETE application, like that caused by HFS or capsaicin, was as-
sociated with an increase in synaptic failures (Figure 5C; average
synaptic failures pre-12-(S)-HPETE application: 35.2% ± 1.9%;
average synaptic failures in 12-(S)-HPETE: 89.7% ± 3.0%;
p < 0.001, n = 6). 12-(S)-HPETE synthesis from arachidonic
acid requires 12-lipoxygenase. To determine whether or not en-
dogenously released 12-(S)-HPETE is responsible for triggering
Neuron
TRPV1-Mediated LTDLTD following synaptic stimulation, we attempted to induce LTD
using HFS in the presence of baicalein (500 nM), an inhibitor of 12-
lipoxygenase. Synaptically induced LTD was blocked in the pres-
ence of baicalein, and in fact in four of ten cells we observed po-
tentiation (greater than 125% of control 20 min following HFS)
(Figure 5D; EPSC amplitudes 15–20 min post-HFS: 129.6% ±
20.3% of control values before HFS; p < 0.01 compared to control
LTD, n = 10). Moreover, the depression caused by 12-(S)-HPETE
was prevented by either capsazepine (10 mM) or SR141716A
(2 mM) (Figures 5E and 5F; EPSC amplitudes after 10–15 min in
12-(S)-HPETE and in the presence of capsazepine: 103.0% ±
8.9% of pre-12-(S)-HPETE control values; p < 0.01 compared
to 12-(S)-HPETE depression in the absence of capsazepine, n = 6;
in 12-(S)-HPETE and in the presence of SR141716A: 106.9% ±
5.5% of pre-12-(S)-HPETE control values; p < 0.01 compared to
12-(S)-HPETE depression in the absence of SR141716A, n = 5).
These observations demonstrate a similar pharmacological
profile for 12-(S)-HPETE and synaptically triggered LTD. Finally,
we found that in slices from Trpv1/ mice, 12-(S)-HPETE did
not depress synaptic transmission at excitatory synapses on in-
terneurons (Figures 5G and 5H; EPSC amplitudes after 10–15
min in 12-(S)-HPETE in Trpv1/ mice: 109.0% ± 6.8% of pre-
drug control values; p = 0.33, n = 6). To rule out any possible
involvement of the retrograde messenger nitric oxide (NO), we
tested whether or not LTD was affected when nitric oxide syn-
thase (NOS) was inhibited. When 200 mM L-NAME was bath
applied 10 min prior to HFS, LTD appeared entirely normal, sug-
gesting that NO does not have a role in this form of synaptic plas-
ticity (EPSC amplitudes 15–20 min post-HFS: 46.3% ± 10.4% of
control values before HFS, n = 5; data not shown). Together, our
data strongly suggest that 12-(S)-HPETE acts at TRPV1 recep-
tors to depress synaptic transmission at excitatory synapses
onto interneurons, and that 12-(S)-HPETE liberated during HFS
is essential for triggering LTD.
Interneurons in stratum radiatum of hippocampal area CA1 re-
ceive their major excitatory synaptic inputs from CA3 pyramidal
cells but can also receive recurrent collaterals from CA1 pyrami-
dal cells (Freund and Buzsaki, 1996). We next tested whether or
not field excitatory postsynaptic potentials (fEPSPs) from syn-
apses between CA3 pyramidal cells and CA1 pyramidal cells
also exhibit TRPV1-mediated synaptic depression. Surprisingly,
1 mM capsaicin, a concentration that significantly depressed ex-
citatory synapses on interneurons (Figures 3A and 3B), did not
depress synapses on CA1 pyramidal cells (Figure 6A; fEPSP
slopes after 10–15 min in capsaicin: 102.8% ± 5.4% of pre-
drug control values; p = 0.58, n = 5). Although 10 mM capsaicin
depressed synaptic transmission at the CA3-CA1 synapse, as
previously reported (Hajos and Freund, 2002), we found that
this was often associated with a depression in the presynaptic fi-
ber volley component of the field potential, suggesting a possible
confounding effect on presynaptic excitability. Furthermore, we
found that 100 nM 12-(S)-HPETE, a concentration that signifi-
cantly depressed excitatory synapses on area CA1 interneurons
(Figure 5A), did not depress synapses between CA3 and CA1
pyramidal cells (Figure 6B; fEPSP slopes after 10–15 min in 12-
(S)-HPETE: 99.0% ± 3.5% of pre-drug control values; p = 0.83,
n = 5). Our data strongly suggest that TRPV1 channel activation
does not depress glutamate release at these CA3 excitatorysynapses onto CA1 hippocampal pyramidal cells, but potently
inhibits excitatory synapses on interneurons in area CA1 stratum
radiatum.
We next investigated the involvement of the recorded inter-
neuron in the generation of LTD. We found that intracellular per-
fusion of recorded interneurons with either GDPbS (250 mM), to
block G protein signaling, or BAPTA (25–40 mM), to chelate post-
synaptic Ca2+, reduced interneuron LTD (Figure 7), a result that
can be explained if lipid retrograde messengers required for
LTD are largely produced by the interneuron. Furthermore, deliv-
ery of the 12-lipoxygenase inhibitor baicalein (140 nM) into the
postsynaptic neuron via the patch pipette also markedly attenu-
ated LTD (Figure 7). Together, these data indicate that the 12-(S)-
HPETE necessary for LTD induction is produced in the recorded
interneuron, and that G protein signaling and postsynaptic Ca2+
play an important role.
Where are the TRPV1 receptors located that must be activated
during LTD? Capsaicin was bath applied to determine whether
we could detect TRPV1-mediated inward currents in different
types of hippocampal neurons. Following bath application of
3 mM capsaicin, inward currents were elicited in both CA3 and
CA1 pyramidal cells (Figure 8A, black bars; peak capsaicin re-
sponse in CA1 pyramidal cells: 160.1 ± 55.3 pA, n = 7; in CA3
Figure 6. Field Potential Recordings from Synapses on CA1 Pyrami-
dal Cells Are Unaffected by Concentrations of Capsaicin or 12-(S)-
HPETE that Depress Synapses on CA1 Interneurons
(A) Field potentials (fEPSPs) recorded at the excitatory synapses between CA3
and CA1 pyramidal cells are not affected by capsaicin (1 mM) (average of five
experiments). Inset: averaged fEPSPs taken from a single experiment before
(black) and after 15 min in capsaicin (gray). Calibration for the insets: 250 mV,
10 ms.
(B) fEPSPs recorded at the excitatory synapses between CA3 and CA1
pyramidal cells are not affected by 12-(S)-HPETE (100 nM) (average of five
experiments). Inset: average of ten fEPSPs taken from a single experiment
before (black) and after 15 min in 12-(S)-HPETE (gray). Error bars indicate
mean ± SEM.Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 753
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TRPV1-Mediated LTDpyramidal cells: 180.1 ± 48.0 pA, n = 5). By contrast, CA1 stratum
radiatum interneurons consistently exhibited little or no response
to 3 mM capsaicin (Figure 8A, black bar; peak capsaicin response
in interneurons: 41.6 ± 16.2 pA; p < 0.05 compared to CA1 and
CA3 pyramidal cell responses, n = 5). In interleaved control ex-
periments, 10 mM capsazepine blocked the effects of 3 mM cap-
saicin application, indicating that the capsaicin-induced inward
currents were caused by TRPV1 receptor activation (Figure 8A).
These results demonstrate the presence of functional TRPV1
receptors on pyramidal cell bodies as well as on some interneu-
rons. The TRPV1 responses on interneurons were variable at
best, suggesting that TRPV1 receptors on interneurons them-
selves do not play a significant role in LTD. To examine this di-
rectly, we delivered the TRPV1 receptor antagonist capsazepine
(2 mM) into the recorded interneuron where it can inhibit the chan-
nel from the inside (Jordt and Julius, 2002). We found intracellular
capsazepine to be ineffective at blocking either synaptically in-
duced LTD or capsaicin-triggered depression (Figures 8B and
8C; EPSC amplitudes 15–20 min post-HFS with intracellular
Figure 7. Intracellular Blockade of G Protein Signaling or the En-
zyme 12-Lipoxygenase, or Chelation of Intracellular Ca2+, Reduces
the Incidence of LTD Triggered by HFS
(A) The amount of synaptic depression present 15–20 min following HFS is
plotted for interneurons under four separate conditions: (1) control intracellular
patch pipette solution (control LTD; open circles, n = 26); (2) patch pipette
solution containing 250 mM GDPbS (filled circles, n = 10); (3) patch pipette so-
lution containing 25–40 mM BAPTA (filled circles, n = 14); and (4) patch pipette
solution containing 140 nM baicalein (filled circles, n = 12). Each circular sym-
bol represents the LTD observed in one experiment. Interneurons were held in
the whole-cell recording configuration for at least 15 min before delivering
HFS. The mean for each population is indicated by the horizontal black bar
within each set of points. The dotted line in this figure represents the mean nor-
malized EPSC value before HFS. Although the average amount of LTD elicited
with each intracellular drug is significantly different from control LTD induced
using control intracellular patch pipette solution (*p < 0.05, **p < 0.01), in
each case there are a few cells that appear to undergo LTD (EPSC amplitudes
15–20 min post-HFS with intracellular GDPbS: 88.2% ± 10.6% of control
values before HFS; p < 0.05 compared to control LTD, n = 10; 6 of 10 cells re-
corded from with intracellular GDPbS had LTD. EPSC amplitudes 15–20 min
post-HFS with intracellular BAPTA: 90.5% ± 8.5% of control values before
HFS; p < 0.01 compared to control LTD, n = 14; 6 of 14 cells recorded from
with intracellular BAPTA had LTD. EPSC amplitudes 15–20 min post-HFS
with intracellular baicalein: 110.8% ± 15.4% of control values before HFS;
p < 0.05 compared to control LTD, n = 12; 4 of 12 cells recorded from with in-
tracellular baicalein had LTD).754 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.capsazepine: 47.5% ± 10.3% of control values before HFS;
p = 0.20 compared to control LTD observed using control intra-
cellular patch pipette solution, n = 7; EPSC amplitudes after
10–15 min in 1 mM capsaicin and in the presence of intracellular
capsazepine: 46.8% ± 10.3% of pre-capsaicin control values;
p < 0.05 compared to capsaicin depression in the absence of
intracellular capsazepine, n = 6). These data indicate that TRPV1
receptors on interneurons are not necessary for LTD, and are
instead consistent with a model in which the TRPV1 receptors
responsible for interneuron LTD might be located on the nerve
terminals of pyramidal cells (Figure 8D).
DISCUSSION
A rapidly growing body of evidence suggests a functional role for
the TRPV channel family in brain function (Marinelli et al., 2003,
2007; Lipski et al., 2006; Marsch et al., 2007; Shibasaki et al.,
2007). This study is the first to our knowledge showing that
TRPV1 receptors are necessary and sufficient for a form of
long-term depression at excitatory synapses. The broad distri-
bution of TRPV1 receptors in the brain suggests that these re-
ceptors could play a similar role in synaptic plasticity throughout
the CNS. TRPV1 receptors might even contribute to some exam-
ples of previously reported endocannabinoid-mediated LTD,
because anandamide can activate TRPV1 in addition to CB1
receptors.
We also report that in the hippocampus at least, 2 mM
SR141716A appears to be insufficiently selective to distinguish
CB1 from TRPV1 receptors. In our study, SR141716A blocked
LTD, in addition to responses to capsaicin and to 12-(S)-HPETE,
whereas the very similar CB1 receptor antagonist AM251 was in-
effective. SR141716A has been shown to attenuate responses to
capsaicin in other systems as well, particularly at concentrations
above 1 mM (Zygmunt et al., 1999; De Petrocellis et al., 2001). A
pharmacological profile similar to what we have observed was
reported for the vasorelaxation of small mesenteric blood ves-
sels that was mediated by an endothelial receptor in response
to NADA, also blocked by SR141716A but not AM251 (O’Sullivan
et al., 2004). Our findings might also relate to previous reports of
a vanilloid receptor-like response at hippocampal excitatory
synapses (Al-Hayani et al., 2001; Hajos and Freund, 2002).
SR141716A (also known as rimonabant or Acomplia) is in wide
clinical use outside the United States as an antiobesity aid (Tucci
et al., 2006; Padwal and Majumdar, 2007). A large percentage of
patients stop taking this drug as a result of psychiatric side ef-
fects, and our findings suggest the possibility that some of the
central effects of rimonabant result from the antagonism of
TRPV1 receptors as well as CB1 receptors (Pegorini et al., 2006).
TRPV1 receptors are expressed in hippocampal neurons
(Mezey et al., 2000; Szabo et al., 2002; Toth et al., 2005; Cristino
et al., 2006) and may be activated in several different ways, in-
cluding by lipoxygenase derivatives that can be released as a re-
sult of group I mGluR activation, as we have shown here (Hwang
et al., 2000; Sohn et al., 2007). 12-(S)-HPETE is known to be re-
leased during field stimulation of hippocampal slices (Feinmark
et al., 2003), and our data indicate that 12-(S)-HPETE production
is necessary and sufficient for LTD at excitatory synapses on
interneurons. Our previous study showed that LTD was triggered
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TRPV1-Mediated LTDsimultaneously at both activated and nonactivated synapses on
interneurons, indicating that the LTD is not synapse specific or
activity dependent (McMahon and Kauer, 1997). The heterosy-
naptic nature of interneuron LTD might be accounted for by
the local spread of 12-(S)-HPETE from interneurons activated
during HFS. The most likely source of this eicosanoid is the re-
corded interneuron itself, based on our data using internally per-
fused drugs; when applied intracellularly to the interneuron the
Ca2+ chelator, BAPTA, the G protein inhibitor, GDPbS, and the
12-lipoxygenase inhibitor, baicalein, all reduced the number of
interneurons exhibiting LTD, suggesting that a Ca2+-sensitive
process, a GPCR-mediated process, and 12-lipoxygenase gen-
eration within the interneuron are necessary for LTD. If pyramidal
cells, whose processes surround stratum radiatum interneurons,
were a significant source of 12-(S)-HPETE following HFS, drugs
delivered intracellularly to the recorded interneuron should not
block LTD. Instead, in most experiments, the intracellularly deliv-
ered drugs blocked LTD (Figure 7). However, in some interneu-
rons even with BAPTA, GDPbS, or baicalein present, LTD of nor-
mal magnitude was induced, suggesting that the necessary
signaling molecules can also arise elsewhere; we favor the
idea that in some cases neighboring interneurons might release
sufficient 12-(S)-HPETE to depress synapses, even when post-
synaptic processes are blocked in the recorded cell. It is alterna-
tively possible that perhaps the heterogeneity of hippocampal
Figure 8. Functional TRPV1Receptors Are Found onPyramidal Cells
and Interneurons, but the TRPV1 Receptor Necessary for LTD Is Not
Located on the Recorded Interneuron
(A) CA1 and CA3 pyramidal cells exhibit a greater peak inward current re-
sponse to capsaicin (3 mM) when compared to CA1 interneurons. The holding
current in three different hippocampal neuron classes was monitored while
capsaicin was bath applied. The peak (mean ± SEM) capsaicin response
(black bars) was significantly reduced in the presence of the TRPV1 receptor
antagonist capsazepine (10 mM; bars marked +) in CA1 and CA3 pyramidal
cells. Peak capsaicin response in the presence of capsazepine: in CA1 pyra-
midal cells: 0.1 ± 0.1 pA; p < 0.05 compared to that without capsazepine,
n = 5; in CA1 interneurons: 0.4 ± 0.2 pA; p = 0.06 compared to that without cap-
sazepine, n = 5; and in CA3 pyramidal cells: 0.1 ± 0.1 pA; p < 0.05 compared to
that in the absence of capsazepine, n = 5). In separate experiments, 1 mM cap-
saicin elicited a small and variable response in pyramidal cells but essentially
no response in interneurons (1 mM capsaicin response in interneurons: 0.7 ±
0.3 pA; p = 0.78 compared to pre-drug control values, n = 5, data not shown).
(B) Intracellular capsazepine does not block LTD. Average of seven experi-
ments with capsazepine (2 mM) included in the intracellular patch pipette solu-
tion. After at least 15 min, HFS was delivered (at the arrow). Inset: average of
ten EPSCs taken from an example neuron just before (black) and at 20 min
after HFS (gray). Calibration for all insets: 100 pA, 10 ms.
(C) Intracellular capsazepine does not prevent capsaicin-induced synaptic de-
pression. Average of six experiments with capsazepine (2 mM) included in the
intracellular patch pipette solution. After at least 15 min, capsaicin (1 mM) was
bath applied to the slice (bar). Inset: average of ten EPSCs taken from an ex-
ample neuron just before (black) and after 10 min in capsaicin (gray). Error bars
indicate mean ± SEM.
(D) Possible scheme to account for the induction of LTD at excitatory synapses
onto CA1 interneurons. Glutamate release during synaptic stimulation acti-
vates mGluR1/5 receptors, leading to the activation of phospholipase
C. Arachidonic acid is converted to 12-(S)-HPETE by a pathway requiring
12-lipoxygenase. 12-(S)-HPETE then activates TRPV1 receptors on presynap-
tic excitatory nerve terminals. Glutamate release is persistently altered, per-
haps by a Ca2+-activated signaling cascade.Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 755
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1996; Parra et al., 1998).
The simplest model to account for our results is that synaptic
stimulation releases glutamate that activates group I mGluRs
producing 12-(S)-HPETE, which might act as a retrograde mes-
senger (Feinmark et al., 2003). 12-(S)-HPETE in turn might open
TRPV1 channels on the presynaptic glutamatergic terminals of
CA1 and/or CA3 pyramidal cells that synapse onto interneurons
(Figure 8D). How might activation of a Ca2+-permeable ion chan-
nel lead to persistent synaptic depression? Calcium entry
through TRPV1 channels on glutamatergic terminals could initi-
ate a signaling cascade responsible for the persistent downregu-
lation of glutamate release observed during LTD. In dorsal root
ganglion neurons, TRPV1 channel opening triggers calcineurin
activation, which then rapidly depresses multiple voltage-gated
calcium channels (Wu et al., 2005, 2006). Moreover, presynaptic
NMDARs are required for spike timing-dependent LTD in neo-
cortical neurons (Sjostrom et al., 2003) and Ca2+ arising from
presynaptic activity is required for LTD at striatal synapses
(Singla et al., 2007), suggesting that presynaptic Ca2+ signals are
required to initiate these forms of LTD as well. However, in both
of these examples, coactive CB1 receptors are also required for
LTD, whereas CB1 receptors are not required for LTD at excit-
atory synapses onto hippocampal interneurons, because
AM251 was ineffective in blocking this form of LTD. The model
we present is the simplest to account for all of our data; however,
although we report here that functional TRPV1 receptors are
present on CA3 and CA1 pyramidal cell bodies, TRPV1 receptors
are also expressed in glial cell populations (Doly et al., 2004; Kim
et al., 2006), so it remains possible that an alternative, more
complex signaling pathway is involved.
TRPV1 was first identified as a heat-sensitive ion channel in pe-
ripheral sensory neurons (Caterina et al., 1997). The temperature
threshold of 43C for TRPV1 channels (Caterina et al., 1997) is
normally outside the brain’s physiological range, but the sensitiv-
ity of the channel to heat and other activating stimuli can be mod-
ulated by endogenous lipids and by the phosphorylation state of
the channel (Vellani et al., 2001; Benham et al., 2003). It is there-
fore conceivable that during fever, TRPV1 channels in the hippo-
campus might be activated, producing LTD at interneuron synap-
ses. Depression of these synapses is expected to increase the
excitability of innervated pyramidal cells. In this regard, it is
intriguing that the in vivo treatment of animals with SR141716A
after the induction of febrile seizures reduced hyperexcitability
in hippocampal area CA1 and prevented the emergence of
long-term limbic hyperexcitability (Chen et al., 2007). Our data
suggest that the blockade of TRPV1 receptors could contribute
to the anticonvulsant effect of SR141716A. The selective depres-
sion of excitatory synapses on interneurons but not on CA1 pyra-
midal cells that we report suggests that TRPV1 receptors are dif-
ferentially distributed on hippocampal excitatory afferents and
offers the potential to target hippocampal inhibitory circuits
selectively through TRPV1 receptors.
Recently, there has been great interest in therapeutic agents
targeting TRPV1 receptors for several disorders, most notably
inflammatory and neuropathic pain (Szallasi and Appendino,
2004; Steenland et al., 2006; Szallasi et al., 2006). Although
drugs binding to peripheral TRPV1 receptors exert analgesic756 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.effects on their own, there is also evidence that TRPV1 receptors
in the CNS are involved in pain modulation and might serve as
useful drug targets (Cui et al., 2006). Our results as well as others
(Marsch et al., 2007) indicate that drugs that bind to CNS TRPV1
receptors are likely to influence more than just pain-related func-
tions. The human hippocampus expresses relatively high levels
of TRPV1 mRNA (Mezey et al., 2000), suggesting that effects
such as those reported here in rodent brain might occur in hu-
mans as well. Further work will help to ascertain whether hippo-
campal TRPV1 receptors could provide novel drug targets for
neurological disorders.
EXPERIMENTAL PROCEDURES
Preparation of Brain Slices
The basic methods have been detailed previously (McMahon and Kauer,
1997). Sprague-Dawley rats (15–22 days old) were used in the majority of ex-
periments. In addition, we used Trpv1/ mice (Caterina et al., 2000) and wild-
type C57BL/6 mice aged between 15 and 21 days (Jackson Laboratory). The
Trpv1/ mice we used have been backcrossed at least ten times onto
a C57BL/6 background and were obtained from homozygous breeding pairs.
Control mice were therefore not littermates but were age-matched, wild-type
C57BL/6 animals received from the same supplier in the same shipment. All
animal protocols were approved by the Brown University Institutional Animal
Care and Use Committee. For mouse experiments, only one brain slice per
mouse was used for each experiment, so that reported n numbers represent
the number of animals. Animals were anaesthetized using halothane or isoflur-
ane and quickly decapitated. The brain was rapidly removed and 300 mm thick
coronal slices were prepared and stored for at least 1 hr submerged on a net in
artificial cerebrospinal fluid (ACSF) containing 119 mM NaCl, 26 mM NaHCO3,
2.5 mM KCl, 1.0 mM NaH2PO4, 2.5 mM CaCl2, 1.3 mM MgSO4, and 11 mM
dextrose, saturated with 95% O2/5% CO2 (pH 7.4). Slices were then trans-
ferred to a submerged recording chamber and bathed in oxygenated ACSF
(28C–32C) containing elevated divalent cations to reduce epileptiform activ-
ity (4 mM CaCl2 and 4 mM MgCl2, replacing MgSO4). A surgical cut was made
between the CA3 and CA1 regions. The storage of slices submerged on a net
rather than in an interface chamber on filter paper might be important in
maintaining slice health and improving the likelihood of observing LTD.
Electrophysiological Recordings from Interneurons
Slices were continuously perfused with ACSF warmed to 28C –32C at a flow
rate of 1–2 ml/min. Picrotoxin (100 mM) and D-AP5 (50 mM) were added to block
GABAA receptor- and NMDAR-mediated synaptic transmission. Whole-cell
patch-clamp recordings were made from interneurons identified visually in the
CA1 stratum radiatum of the hippocampus. No specific cell morphology was
targeted, although we did not record from cells with the ‘‘giant cell’’ morphology
as these have been reported to be glutamatergic interneurons (Gulyas et al.,
1998). Patch pipettes were filled with internal recording solution containing
117 mM cesium gluconate, 2.8 mM NaCl, 5 mM MgCl2, 20 mM HEPES, 2 mM
ATP-Na+, 0.3mM GTP-Na+, and 0.6 mM EGTA. In some experiments, 2mM cap-
sazepine, 140 nM baicalein, or 250 mM GDPbS were also included in the intra-
cellular patch pipette solution. In experiments with BAPTA-containing patch
electrodes, EGTA was omitted from the intracellular solution and 25 or 40 mM
BAPTA replaced a corresponding amount of cesium gluconate. EPSCs were
stimulated at 0.1 Hz (100 ms) using a bipolar stainless steel stimulating electrode
placed in stratum radiatum at least 200mm from the recorded cell. CA1 interneu-
rons were voltage clamped at 65 mV (not corrected for the liquid junction po-
tential of10 mV), and EPSCs were evoked by paired pulses with an interval of
50 ms (stimulus intensity typically 50–400 mA). In early experiments, we mea-
sured rectification ratios of EPSCs evoked at +40 mV/60 mV in the presence
of 50 mM D-AP5, measured at the time of peak inward synaptic current seen at
70 mV (Lei and McBain, 2004). Rectification ratios did not correlate with the in-
cidence of LTD: interneurons with no LTD, 0.63 ± 0.19, n = 3, range 0.25–0.86;
interneurons with transient LTD, 0.47 ± 0.05, n = 4, range 0.42–0.52; interneu-
rons with persistent LTD, 0.58 ± 0.11, n = 9, range 0.11–1.28.
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TRPV1-Mediated LTDHigh-frequency stimulation was used to induce LTD (HFS; two 1 s trains at
100 Hz, intertrain interval 20 s, at 1.5 times test current intensity) with the neu-
ron held in current-clamp mode, so that the HFS trains were delivered with the
membrane potential free to vary. Receptor antagonists were added directly to
the ACSF at known concentrations for at least 10 min prior to HFS. Control ex-
periments were interleaved with those experiments using receptor antagonists
or involving slices from Trpv1/ mice. The cell input resistance and series re-
sistance were monitored throughout each experiment; cells were discarded if
these values changed by more than 10% during the experiment. EPSCs were
amplified using an AxoClamp 2B amplifier (Axon Instruments) and Brownlee
Precision model 410 postamplifier (AutoMate Scientific), low-pass filtered at
3 kHz, and digitally sampled to a PC at 30 kHz using an analog-to-digital inter-
face (National Instruments).
Field EPSP Recordings
Extracellular field potential recordings were made from synapses between
CA3 and CA1 pyramidal cells in hippocampal slices prepared from rats as pre-
viously described (McMahon and Kauer, 1997). Briefly, 400 mm thick coronal
slices were cut using a vibratome, and individual slices were stored for at least
1 hr submerged on a net in ACSF. Slices were then transferred to a submersion
chamber and held between two nylon nets. The chamber was constantly per-
fused with high-divalent ACSF including 100 mM picrotoxin, oxygenated, and
warmed to 29C–31C at a flow rate of 2–3 ml/min. A bipolar stainless steel
stimulating electrode placed in stratum radiatum was used to stimulate CA1
field potentials, while a recording electrode filled with 2 M NaCl was positioned
about 500 mm from the stimulating electrode in stratum radiatum. Stimuli
(intensity typically 50–200 mA, 100 ms duration) were delivered at 0.1 Hz and
the current intensity was adjusted to elicit an fEPSP of 0.5 mV at the start of
each experiment. fEPSPs were amplified using an AxoPatch 1D amplifier
(Axon Instruments) and Brownlee Precision model 410 postamplifier (Auto-
Mate Scientific), low-pass filtered at 1–2 kHz, and digitally sampled to a PC
at 10–20 kHz using an analog-to-digital interface (National Instruments). Cap-
saicin (1 mM) or 12-(S)-HPETE (100 nM) were added directly to the ACSF
bathing solution after at least a 15 min baseline period of consistent fEPSPs.
Analysis
The maximal initial slope of fEPSPs was calculated using a LabVIEW-based
program (National Instruments). The peak amplitude of each EPSC was mea-
sured by comparing a 10 ms time period immediately prior to the stimulus with
the peak of the EPSC using this program as well. Occasionally polysynaptic re-
sponses were evoked, and in these cases only the initial monosynaptic event
was measured. To positively identify LTD, EPSCs measured every 10 s were
averaged in 1 min intervals. EPSC amplitude values were normalized to control
pre-HFS EPSC amplitude values (baseline period of at least 5 min prior to HFS)
and subjected to analysis of variance (ANOVA) repeated-measures analysis
with a post-hoc Dunnett’s test (GraphPad Prism, Version 4). A significant de-
crease (p < 0.05) in EPSC amplitude in 5 min periods following HFS that per-
sisted more than 10 min post-HFS indicated that LTD had been induced.
EPSC amplitude values 15–20 min post-HFS were compared between control
LTD experiments and those carried out either in transgenic Trpv1/ mice or in
the presence of drug using a t test (unpaired, two-tailed, with Welch’s correc-
tion if the variances between the groups were unequal). To calculate the effects
of capsaicin, 12-(S)-HPETE, or WIN 55,212-2 application on basal excitatory
glutamatergic transmission, normalized EPSC amplitudes or fEPSP slopes
were averaged in the final 5 min of drug application and compared with
EPSCs/EPSPs 5 min prior to drug application. In addition, to measure capsa-
icin’s effects on holding current, the peak change in holding current was mea-
sured during bath application of 3 mM capsaicin. The n values reported refer to
the number of slices. All combined data are expressed as mean ± the standard
error of the mean (SEM). All results reported in this study were significant to at
least p < 0.05.
Paired-pulse ratios (PPR; EPSC2/EPSC1) and coefficient of variation (1/CV2)
were calculated within 5 min epochs of 30 EPSCs each, starting 5 min imme-
diately before HFS or drug addition. The PPR was calculated by dividing the
mean of all 30 EPSC2 amplitudes by the mean of all 30 corresponding
EPSC1 amplitudes within each epoch. 1/CV2 was determined by dividing
the squared mean amplitude of 30 EPSCs within 5 min epochs by the varianceof these EPSC amplitudes. Experiments in which the EPSC was depressed by
more than 10% in response to HFS were included in the PPR and 1/CV2 anal-
yses. Given that in some of the experiments the synaptic depression following
HFS returned to baseline values after 15–20 min, we are most confident of the
PPR and 1/CV2 data over the 20 min time period immediately following HFS.
For statistical analysis of significance of the changes in nonnormalized values
of 1/CV2 and PPR, we used distribution-free, nonparametric inferential statis-
tics (Wilcoxon matched-pairs signed-ranks test) to assess these values ob-
tained from the same cell before and after HFS with a significance level of
p < 0.05. Nonparametric statistics were used because the response values
did not meet assumptions of normality and homogeneity of variance.
For synaptic failure analysis, EPSCs were evoked using minimal stimulation
intensities that resulted in at least 20% failures of synaptic transmission. The
number of failures for each experiment was determined by eye for the baseline
period of at least 10 min; the largest amplitude value associated with a failure
was then defined as the threshold value for individual failures in that experi-
ment. This analysis necessarily groups both failures of transmitter release
and transmission failures. Failures reported in the figures were assessed as
the percentage of failures occurring during a 10 min control baseline period,
for the 15–20 min time period post-HFS (Figure 1E) or for the 10–15 min time
period following the application of capsaicin or 12-(S)-HPETE (Figures 3C
and 5C).
Materials
SR141716A was generously provided by the National Institute on Drug Abuse
(NIDA). 12-(S)-HPETE (12-[S]-hydroperoxyeicosa-5Z,8Z,10E,14Z-tetraenoic
acid) was purchased from Biomol International and BAPTA (1,2-bis[o-amino-
phenoxy]ethane-N,N,N0,N0 tetraacetic acid) was purchased from Calbiochem.
AM251, baicalein, capsaicin, capsazepine, CPCCOEt (7-[hydroxyimino]cyclo-
propa[b]chromen-1a-carboxylate ethyl ester), D-AP5 (D-[]-2-amino-5-phos-
phonovaleric acid), 50-iodoresiniferatoxin, L-NAME, and WIN 55,212-2 mesy-
late were obtained from Tocris Bioscience. All other chemicals were
purchased from Sigma-Aldrich. AM251, baicalein, capsaicin, capsazepine,
CPCCOEt, 50-iodoresiniferatoxin, SR141716A, and WIN 55,212-2 mesylate
were dissolved in DMSO and then diluted at least 1:1000 to the final concen-
tration in ACSF, or for baicalein and capsazepine, at least 1:5000 to the final
concentration in the intracellular patch pipette solution. Control experiments
showed that 0.1% DMSO did not block LTD (EPSC amplitudes post-HFS:
67.7% ± 17.8% of baseline values, n = 3; not significantly different from control
LTD).
ACKNOWLEDGMENTS
The authors thank Barry Connors and Robert Malenka as well as members of
our lab for helpful discussions and reading of the manuscript, Kevin Gormley at
NIDA for providing SR141716A, and Jeannette Downing-Park for technical
assistance. This work was supported by National Institutes of Health grants
DA11289, NS050570 (J.A.K.), and NS049779 (J.G.E.).
Received: July 20, 2007
Revised: November 15, 2007
Accepted: December 26, 2007
Published: March 12, 2008
REFERENCES
Al-Hayani, A., Wease, K.N., Ross, R.A., Pertwee, R.G., and Davies, S.N.
(2001). The endogenous cannabinoid anandamide activates vanilloid recep-
tors in the rat hippocampal slice. Neuropharmacology 41, 1000–1005.
Benham, C.D., Gunthorpe, M.J., and Davis, J.B. (2003). TRPV channels as
temperature sensors. Cell Calcium 33, 479–487.
Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D.,
and Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in
the pain pathway. Nature 389, 816–824.
Caterina, M.J., Leffler, A., Malmberg, A.B., Martin, W.J., Trafton, J., Petersen-
Zeitz, K.R., Koltzenburg, M., Basbaum, A.I., and Julius, D. (2000). ImpairedNeuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 757
Neuron
TRPV1-Mediated LTDnociception and pain sensation in mice lacking the capsaicin receptor.
Science 288, 306–313.
Chen, K., Neu, A., Howard, A.L., Foldy, C., Echegoyen, J., Hilgenberg, L.,
Smith, M., Mackie, K., and Soltesz, I. (2007). Prevention of plasticity of endo-
cannabinoid signaling inhibits persistent limbic hyperexcitability caused by
developmental seizures. J. Neurosci. 27, 46–58.
Chevaleyre, V., and Castillo, P.E. (2003). Heterosynaptic LTD of hippocampal
GABAergic synapses: a novel role of endocannabinoids in regulating excitabil-
ity. Neuron 38, 461–472.
Chevaleyre, V., and Castillo, P.E. (2004). Endocannabinoid-mediated meta-
plasticity in the hippocampus. Neuron 43, 871–881.
Chevaleyre, V., Takahashi, K.A., and Castillo, P.E. (2006). Endocannabinoid-
mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29, 37–76.
Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., and
Di Marzo, V. (2006). Immunohistochemical localization of cannabinoid type 1
and vanilloid transient receptor potential vanilloid type 1 receptors in the
mouse brain. Neuroscience 139, 1405–1415.
Cui, M., Honore, P., Zhong, C., Gauvin, D., Mikusa, J., Hernandez, G.,
Chandran, P., Gomtsyan, A., Brown, B., Bayburt, E.K., et al. (2006). TRPV1
receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1
antagonists. J. Neurosci. 26, 9385–9393.
del Castillo, J., and Katz, B. (1954). Quantal components of the end-plate
potential. J. Physiol. 124, 560–573.
De Petrocellis, L., and Di Marzo, V. (2005). Lipids as regulators of the activity of
transient receptor potential type V1 (TRPV1) channels. Life Sci. 77, 1651–1666.
De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J.B., Finazzi-Agro, A.,
and Di Marzo, V. (2001). The activity of anandamide at vanilloid VR1 receptors
requires facilitated transport across the cell membrane and is limited by
intracellular metabolism. J. Biol. Chem. 276, 12856–12863.
Doly, S., Fischer, J., Salio, C., and Conrath, M. (2004). The vanilloid receptor-1
is expressed in rat spinal dorsal horn astrocytes. Neurosci. Lett. 357, 123–126.
Feinmark, S.J., Begum, R., Tsvetkov, E., Goussakov, I., Funk, C.D., Siegel-
baum, S.A., and Bolshakov, V.Y. (2003). 12-lipoxygenase metabolites of
arachidonic acid mediate metabotropic glutamate receptor-dependent
long-term depression at hippocampal CA3-CA1 synapses. J. Neurosci. 23,
11427–11435.
Ferraguti, F., Cobden, P., Pollard, M., Cope, D., Shigemoto, R., Watanabe, M.,
and Somogyi, P. (2004). Immunolocalization of metabotropic glutamate recep-
tor 1a (mGluR1a) in distinct classes of interneuron in the CA1 region of the rat
hippocampus. Hippocampus 14, 193–215.
Freund, T.F., and Buzsaki, G. (1996). Interneurons of the hippocampus. Hippo-
campus 6, 347–470.
Gerdeman, G.L., Ronesi, J., and Lovinger, D.M. (2002). Postsynaptic endo-
cannabinoid release is critical to long-term depression in the striatum. Nat.
Neurosci. 5, 446–451.
Gulyas, A.I., Toth, K., McBain, C.J., and Freund, T.F. (1998). Stratum radiatum
giant cells: a type of principal cell in the rat hippocampus. Eur. J. Neurosci. 10,
3813–3822.
Hajos, N., and Freund, T.F. (2002). Pharmacological separation of cannabinoid
sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuro-
pharmacology 43, 503–510.
Holzer, P. (1988). Local effector functions of capsaicin-sensitive sensory nerve
endings: involvement of tachykinins, calcitonin gene-related peptide and other
neuropeptides. Neuroscience 24, 739–768.
Huang, S.M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L.,
Fezza, F., Tognetto, M., Petros, T.J., Krey, J.F., Chu, C.J., et al. (2002). An
endogenous capsaicin-like substance with high potency at recombinant and
native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA 99, 8400–8405.
Hwang, S.W., Cho, H., Kwak, J., Lee, S.Y., Kang, C.J., Jung, J., Cho, S., Min,
K.H., Suh, Y.G., Kim, D., et al. (2000). Direct activation of capsaicin receptors
by products of lipoxygenases: endogenous capsaicin-like substances. Proc.
Natl. Acad. Sci. USA 97, 6155–6160.758 Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc.Jordt, S.E., and Julius, D. (2002). Molecular basis for species-specific sensitiv-
ity to ‘‘hot’’ chili peppers. Cell 108, 421–430.
Kim, S.R., Kim, S.U., Oh, U., and Jin, B.K. (2006). Transient receptor potential
vanilloid subtype 1 mediates microglial cell death in vivo and in vitro via Ca2+-
mediated mitochondrial damage and cytochrome c release. J. Immunol. 177,
4322–4329.
Kreitzer, A.C., and Regehr, W.G. (2001). Retrograde inhibition of presynaptic
calcium influx by endogenous cannabinoids at excitatory synapses onto
Purkinje cells. Neuron 29, 717–727.
Kreitzer, A.C., and Malenka, R.C. (2005). Dopamine modulation of state-de-
pendent endocannabinoid release and long-term depression in the striatum.
J. Neurosci. 25, 10537–10545.
Kullmann, D.M., and Lamsa, K.P. (2007). Long-term synaptic plasticity in
hippocampal interneurons. Nat. Rev. Neurosci. 8, 687–699.
Lei, S., and McBain, C.J. (2004). Two loci of expression for long-term depres-
sion at hippocampal mossy fiber-interneuron synapses. J. Neurosci. 24, 2112–
2121.
Lipski, J., Park, T.I., Li, D., Lee, S.C., Trevarton, A.J., Chung, K.K., Freestone,
P.S., and Bai, J.Z. (2006). Involvement of TRP-like channels in the acute ische-
mic response of hippocampal CA1 neurons in brain slices. Brain Res. 1077,
187–199.
Llano, I., Leresche, N., and Marty, A. (1991). Calcium entry increases the sen-
sitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory
synaptic currents. Neuron 6, 565–574.
Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A., and Kano, M. (2001). Presyn-
aptic inhibition caused by retrograde signal from metabotropic glutamate to
cannabinoid receptors. Neuron 31, 463–475.
Malenka, R.C., and Bear, M.F. (2004). LTP and LTD: an embarrassment of
riches. Neuron 44, 5–21.
Malinow, R., and Tsien, R.W. (1990). Presynaptic enhancement shown by
whole-cell recordings of long-term potentiation in hippocampal slices. Nature
346, 177–180.
Manabe, T., Renner, P., and Nicoll, R.A. (1992). Postsynaptic contribution to
long-term potentiation revealed by the analysis of miniature synaptic currents.
Nature 355, 50–55.
Mann, E.O., and Paulsen, O. (2007). Role of GABAergic inhibition in hippocam-
pal network oscillations. Trends Neurosci. 30, 343–349.
Marinelli, S., Di Marzo, V., Berretta, N., Matias, I., Maccarrone, M., Bernardi,
G., and Mercuri, N.B. (2003). Presynaptic facilitation of glutamatergic synap-
ses to dopaminergic neurons of the rat substantia nigra by endogenous stim-
ulation of vanilloid receptors. J. Neurosci. 23, 3136–3144.
Marinelli, S., Di Marzo, V., Florenzano, F., Fezza, F., Viscomi, M.T., van der
Stelt, M., Bernardi, G., Molinari, M., Maccarrone, M., and Mercuri, N.B.
(2007). N-arachidonoyl-dopamine tunes synaptic transmission onto dopami-
nergic neurons by activating both cannabinoid and vanilloid receptors. Neuro-
psychopharmacology 32, 298–308.
Marsch, R., Foeller, E., Rammes, G., Bunck, M., Kossl, M., Holsboer, F., Ziegl-
gansberger, W., Landgraf, R., Lutz, B., and Wotjak, C.T. (2007). Reduced
anxiety, conditioned fear, and hippocampal long-term potentiation in transient
receptor potential vanilloid type 1 receptor-deficient mice. J. Neurosci. 27,
832–839.
Matta, J.A., Miyares, R.L., and Ahern, G.P. (2007). TRPV1 is a novel target for
omega-3 polyunsaturated fatty acids. J. Physiol. 578, 397–411.
McMahon, L.L., and Kauer, J.A. (1997). Hippocampal interneurons express
a novel form of synaptic plasticity. Neuron 18, 295–305.
Mezey, E., Toth, Z.E., Cortright, D.N., Arzubi, M.K., Krause, J.E., Elde, R., Guo,
A., Blumberg, P.M., and Szallasi, A. (2000). Distribution of mRNA for vanilloid
receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central
nervous system of the rat and human. Proc. Natl. Acad. Sci. USA 97, 3655–
3660.
Ohno-Shosaku, T., Maejima, T., and Kano, M. (2001). Endogenous cannabi-
noids mediate retrograde signals from depolarized postsynaptic neurons to
presynaptic terminals. Neuron 29, 729–738.
Neuron
TRPV1-Mediated LTDO’Sullivan, S.E., Kendall, D.A., and Randall, M.D. (2004). Characterisation of
the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-
dopamine (NADA). Br. J. Pharmacol. 141, 803–812.
Padwal, R.S., and Majumdar, S.R. (2007). Drug treatments for obesity: orlistat,
sibutramine, and rimonabant. Lancet 369, 71–77.
Parra, P., Gulyas, A.I., and Miles, R. (1998). How many subtypes of inhibitory
cells in the hippocampus? Neuron 20, 983–993.
Pegorini, S., Zani, A., Braida, D., Guerini-Rocco, C., and Sala, M. (2006). Vanil-
loid VR1 receptor is involved in rimonabant-induced neuroprotection. Br.
J. Pharmacol. 147, 552–559.
Pitler, T.A., and Alger, B.E. (1992). Postsynaptic spike firing reduces synaptic
GABAA responses in hippocampal pyramidal cells. J. Neurosci. 12, 4122–
4132.
Robbe, D., Kopf, M., Remaury, A., Bockaert, J., and Manzoni, O.J. (2002). En-
dogenous cannabinoids mediate long-term synaptic depression in the nucleus
accumbens. Proc. Natl. Acad. Sci. USA 99, 8384–8388.
Roberts, J.C., Davis, J.B., and Benham, C.D. (2004). [3H]resiniferatoxin auto-
radiography in the CNS of wild-type and TRPV1 null mice defines TRPV1
(VR-1) protein distribution. Brain Res. 995, 176–183.
Ronesi, J., Gerdeman, G.L., and Lovinger, D.M. (2004). Disruption of endocan-
nabinoid release and striatal long-term depression by postsynaptic blockade
of endocannabinoid membrane transport. J. Neurosci. 24, 1673–1679.
Sanchez, J.F., Krause, J.E., and Cortright, D.N. (2001). The distribution and
regulation of vanilloid receptor VR1 and VR1 50 splice variant RNA expression
in rat. Neuroscience 107, 373–381.
Sasamura, T., Sasaki, M., Tohda, C., and Kuraishi, Y. (1998). Existence of
capsaicin-sensitive glutamatergic terminals in rat hypothalamus. Neuroreport
9, 2045–2048.
Shibasaki, K., Suzuki, M., Mizuno, A., and Tominaga, M. (2007). Effects of body
temperature on neural activity in the hippocampus: regulation of resting
membrane potentials by transient receptor potential vanilloid 4. J. Neurosci.
27, 1566–1575.
Shin, J., Cho, H., Hwang, S.W., Jung, J., Shin, C.Y., Lee, S.Y., Kim, S.H., Lee,
M.G., Choi, Y.H., Kim, J., et al. (2002). Bradykinin-12-lipoxygenase-VR1
signaling pathway for inflammatory hyperalgesia. Proc. Natl. Acad. Sci. USA
99, 10150–10155.
Singla, S., Kreitzer, A.C., and Malenka, R.C. (2007). Mechanisms for synapse
specificity during striatal long-term depression. J. Neurosci. 27, 5260–5264.
Sjostrom, P.J., Turrigiano, G.G., and Nelson, S.B. (2003). Neocortical LTD via
coincident activation of presynaptic NMDA and cannabinoid receptors.
Neuron 39, 641–654.
Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Cham-
bers, J.K., Randall, A.D., and Davis, J.B. (2000). The endogenous lipid ananda-
mide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol.
129, 227–230.
Sohn, J.W., Lee, D., Cho, H., Lim, W., Shin, H.S., Lee, S.H., and Ho, W.K.
(2007). Receptor-specific inhibition of GABAB-activated K+ currents by mus-carinic and metabotropic glutamate receptors in immature rat hippocampus.
J. Physiol. 580, 411–422.
Steenland, H.W., Ko, S.W., Wu, L.J., and Zhuo, M. (2006). Hot receptors in the
brain. Mol. Pain 2, 34.
Szabo, T., Biro, T., Gonzalez, A.F., Palkovits, M., and Blumberg, P.M. (2002).
Pharmacological characterization of vanilloid receptor located in the brain.
Brain Res. Mol. Brain Res. 98, 51–57.
Szallasi, A., and Blumberg, P.M. (1999). Vanilloid (capsaicin) receptors and
mechanisms. Pharmacol. Rev. 51, 159–212.
Szallasi, A., and Appendino, G. (2004). Vanilloid receptor TRPV1 antagonists
as the next generation of painkillers. Are we putting the cart before the horse?
J. Med. Chem. 47, 2717–2723.
Szallasi, A., Cruz, F., and Geppetti, P. (2006). TRPV1: a therapeutic target for
novel analgesic drugs? Trends Mol. Med. 12, 545–554.
Takahashi, K.A., and Castillo, P.E. (2006). The CB1 cannabinoid receptor me-
diates glutamatergic synaptic suppression in the hippocampus. Neuroscience
139, 795–802.
Tominaga, M., Caterina, M.J., Malmberg, A.B., Rosen, T.A., Gilbert, H.,
Skinner, K., Raumann, B.E., Basbaum, A.I., and Julius, D. (1998). The cloned
capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21,
531–543.
Toth, A., Boczan, J., Kedei, N., Lizanecz, E., Bagi, Z., Papp, Z., Edes, I., Csiba,
L., and Blumberg, P.M. (2005). Expression and distribution of vanilloid receptor
1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain Res. 135, 162–168.
Tucci, S.A., Halford, J.C., Harrold, J.A., and Kirkham, T.C. (2006). Therapeutic
potential of targeting the endocannabinoids: implications for the treatment of
obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med.
Chem. 13, 2669–2680.
Van Der Stelt, M., and Di Marzo, V. (2004). Endovanilloids. Putative endoge-
nous ligands of transient receptor potential vanilloid 1 channels. Eur.
J. Biochem. 271, 1827–1834.
Vellani, V., Mapplebeck, S., Moriondo, A., Davis, J.B., and McNaughton, P.A.
(2001). Protein kinase C activation potentiates gating of the vanilloid receptor
VR1 by capsaicin, protons, heat and anandamide. J. Physiol. 534, 813–825.
Wilson, R.I., and Nicoll, R.A. (2001). Endogenous cannabinoids mediate retro-
grade signalling at hippocampal synapses. Nature 410, 588–592.
Wu, Z.Z., Chen, S.R., and Pan, H.L. (2005). Transient receptor potential vanil-
loid type 1 activation down-regulates voltage-gated calcium channels through
calcium-dependent calcineurin in sensory neurons. J. Biol. Chem. 280, 18142–
18151.
Wu, Z.Z., Chen, S.R., and Pan, H.L. (2006). Signaling mechanisms of down-
regulation of voltage-activated Ca2+ channels by transient receptor potential
vanilloid type 1 stimulation with olvanil in primary sensory neurons. Neurosci-
ence 141, 407–419.
Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H., Sorgard, M., Di
Marzo, V., Julius, D., and Hogestatt, E.D. (1999). Vanilloid receptors on
sensory nerves mediate the vasodilator action of anandamide. Nature 400,
452–457.Neuron 57, 746–759, March 13, 2008 ª2008 Elsevier Inc. 759
